Trial Profile

Efficacy and safety of albumin-bound paclitaxel, cisplatin and capecitabine in combination with sequential concurrent chemoradiotherapy combined with apatinib and camrelizumab for stage N3M0 nasopharyngeal carcinoma: a prospective, open labeled phase II clinical trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
Indications Carcinoma; Nasopharyngeal cancer
Focus Therapeutic Use
Acronyms QUINTUPLED trial

07 Jun 2022 Results (n=50) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
04 Aug 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com